

# A-Engrossed House Bill 4028

Ordered by the House February 23  
Including House Amendments dated February 23

Introduced and printed pursuant to House Rule 12.00. Pre-session filed (at the request of House Interim Committee on Rules for Representative Julie Fahey)

## SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure. The statement includes a measure digest written in compliance with applicable readability standards.

**Digest: The Act prohibits drug makers from taking actions that make it hard for a drug store to get certain drugs on behalf of certain types of health care providers or deliver the drugs to the providers. The Act also prohibits drug makers from taking actions that make it hard for drug stores to deliver the drugs to the providers. (Flesch Readability Score: 63.5).**

*[Digest: The Act requires the OHA to study the problems in getting health care in this state and to send a report of its findings to the legislature. The section is repealed on January 2, 2026. (Flesch Readability Score: 60.9).]*

*[Requires the Oregon Health Authority to study access to health care in this state. Directs the authority to submit its findings to the interim committees of the Legislative Assembly related to health not later than September 15, 2025.]*

**Prohibits drug manufacturers from interfering directly or indirectly with a pharmacy or drug outlet acquiring 340B drugs for or delivering 340B drugs to certain health care providers.**

## A BILL FOR AN ACT

1  
2 Relating to health care.

3 **Be It Enacted by the People of the State of Oregon:**

4 **SECTION 1. (1) As used in this section:**

5 (a) **“Covered entity”** has the meaning given that term in 42 U.S.C. 256b(a)(4).

6 (b) **“Manufacturer”** has the meaning given that term in ORS 646A.689.

7 (c) **“340B drug”** means a drug that has been subject to any offer of a reduced price by a  
8 manufacturer pursuant to 42 U.S.C. 256b and is purchased by a covered entity.

9 (2) **A manufacturer may not deny, restrict, prohibit or otherwise interfere directly or**  
10 **indirectly with the acquisition of a 340B drug or the delivery of a 340B drug to a pharmacy**  
11 **or drug outlet that has contracted with a covered entity to receive and dispense 340B drugs**  
12 **on behalf of the covered entity unless the acquisition or delivery is prohibited by the United**  
13 **States Department of Health and Human Services.**

14  

---

  
**NOTE:** Matter in **boldfaced** type in an amended section is new; matter *[italic and bracketed]* is existing law to be omitted. New sections are in **boldfaced** type.